Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Recent Advances in Pulmonary Hypertension
Author(s): Akshyaya Pradhan , Richa Tyagi , Prachi Sharma , et al Added: 6 months ago

Heart Failure

Prevention & Chronic Conditions
TCT 24: The ECLIPSE Trial
Author(s): Ajay J Kirtane Added: 8 months ago
TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott… View more

Intervention
TCT 24: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty
Author(s): Ulf Teichgräber Added: 8 months ago
TCT Conference 2024 - Safety and efficacy outcomes of the trial shows that percutaneous transluminal angioplasty (PTA) with the sirolimus drug coated balloon (DCB) in patients with femoropopliteal artery disease was/was not noninferior to PTA with the paclitaxel DCB.Prof Ulf Teichgräber joins us onsite at TCT Conference to discuss the findings from the sirolimus- vs. paclitaxel-coated balloon… View more

Intervention

Vascular Disease and Surgery
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 1 year ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
TCT 24: The PEERLESS Trial
Author(s): Dr Wissam A Jaber Added: 7 months ago
TCT Conference 24 - PEERLESS II shows benefit of large-bore mechanical thrombectomy compared to catheter-directed thrombolysis for intermediate-risk pulmonary embolism (PE) patients.Dr Wissam A Jaber (Emory University Hospital Midtown, US) joins us onsite at TCT Conference to discuss the findings from PEERLESS (NCT06055920; Inari Medical).PEERLESS is a prospective, multicenter, randomized… View more

Anticoagulation

Intervention
ACC.24: The SMART Trial
Author(s): Howard C Herrmann Added: 1 year ago
ACC.24 — Investigator, Dr Howard C Hermann (Penn Medicine, Philadelphia, PA, US) joins us to discuss the findings from the SMART Trial (NCT04722250).This prospective, multi-center, randomized controlled study aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli… View more

Intervention
ESC 24: SHAM-PVI: Sham Study of Pulmonary Vein Isolation in Symptomatic Atrial Fibrillation
Author(s): Rick Veasey Added: 10 months ago
ESC Congress 24 — SHAM-PVI study finds pulmonary vein isolation effective in reducing atrial fibrillation (AF) episodes, improving quality of life.We are joined onsite by Dr Rick Veasey (Eastbourne District General Hospital, Eastbourne, UK) to discuss the findings from a SHAM-PVI, a randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (NCT04272762; East… View more

Electrophysiology & Arrhythmia
AHA 23: Ultrasound-assisted Thrombolysis Vs Pulmonary Embolectomy for PE
Author(s): Stefan Stortecky Added: 1 year ago
AHA 23 — We are joined onsite by Prof Stefan Stortecky (Bern University Hospital, Bern, SE) to discuss the findings of the single centre SPECIAL trial that investigated ultrasound-assisted catheter-directed thrombolysis as compared to surgical pulmonary embolectomy for intermediate high or high risk pulmonary embolism.Questions1. What is the reasoning behind this study?2. What is the patient… View more

Vascular Disease and Surgery
AHA 23: KABUKI: DOAC in Pts with CTEPH
Author(s): Kazuya Hosokawa , Abe Kotaro Added: 1 year ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3… View more

Prevention & Chronic Conditions
Repeat TAVR Outcomes: Promising Results for Selected Patients with Failed TAVR
Author(s): Raj Makkar Added: 1 year ago
In this insightful interview, investigator, Prof Raj R Makkar(Cedars-Sinai Heart Institute, US) joins us to discuss the outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves. Prof Makkar and his team used the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to address a series of questions regarding the safety… View more

Intervention